{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:28Z","timestamp":1790805148847,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model of PD to compare the efficacy of hepatic gene transfer with adeno-associated virus (AAV) vectors expressing secretable GAA with long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene transfer with pharmacological chaperones boosts GAA bioavailability, resulting in improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to non-human primates also successfully results in enzyme secretion in blood and uptake in key target tissues, supporting the ongoing clinical translation of the approach.<\/jats:p>","DOI":"10.1038\/s41467-021-26744-4","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:37:43Z","timestamp":1636025863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-2156","authenticated-orcid":false,"given":"Helena","family":"Costa-Verdera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-7290","authenticated-orcid":false,"given":"Fanny","family":"Collaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Riling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Sellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme M. L.","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Cagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Fabregue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Moya-Nilges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacomina","family":"Krijnse-Locker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"van Wittenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gjata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Cosette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Simon-Sola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Crosariol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Antrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William J.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-307X","authenticated-orcid":false,"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier M.","family":"Anguela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-4324","authenticated-orcid":false,"given":"Sean M.","family":"Armour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-2391","authenticated-orcid":false,"given":"Pasqualina","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-0210","authenticated-orcid":false,"given":"Giuseppe","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0685-3752","authenticated-orcid":false,"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"26744_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler, L., Puertollano, R. & Raben, N. Pompe disease: from basic science to therapy. Neurotherapeutics 15, 928\u2013942 (2018).","journal-title":"Neurotherapeutics"},{"key":"26744_CR2","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","volume":"40","author":"AJJ Reuser","year":"2019","unstructured":"Reuser, A. J. J. et al. GAA variants and phenotypes among 1079 patients with Pompe disease: data from the Pompe registry. Hum. Mutat. 40, 2146\u20132164 (2019).","journal-title":"Hum. Mutat."},{"key":"26744_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm.2019.05.56","volume":"7","author":"BJ Byrne","year":"2019","unstructured":"Byrne, B. J. et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Ann. Transl. Med. 7, 290 (2019).","journal-title":"Ann. Transl. Med."},{"key":"26744_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21037\/atm.2019.04.49","volume":"7","author":"A Korlimarla","year":"2019","unstructured":"Korlimarla, A., Lim, J. A., Kishnani, P. S. & Sun, B. An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. Ann. Transl. Med. 7, 289 (2019).","journal-title":"Ann. Transl. Med."},{"key":"26744_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.21037\/atm.2019.07.24","volume":"7","author":"A Toscano","year":"2019","unstructured":"Toscano, A., Rodolico, C. & Musumeci, O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann. Transl. Med. 7, 284 (2019).","journal-title":"Ann. Transl. Med."},{"key":"26744_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","volume":"1793","author":"T Braulke","year":"2009","unstructured":"Braulke, T. & Bonifacino, J. S. Sorting of lysosomal proteins. Biochim. Biophys. Acta 1793, 605\u2013614 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"26744_CR7","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"HA Wisselaar","year":"1993","unstructured":"Wisselaar, H. A., Kroos, M. A., Hermans, M. M., van Beeumen, J. & Reuser, A. J. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J. Biol. Chem. 268, 2223\u20132231 (1993).","journal-title":"J. Biol. Chem."},{"key":"26744_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani, P. S. et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. 149, 89\u201397 (2006).","journal-title":"J. Pediatr."},{"key":"26744_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A. T. et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N. Engl. J. Med. 362, 1396\u20131406 (2010).","journal-title":"N. Engl. J. Med."},{"key":"26744_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg, A. T. et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol. Genet. Metab. 107, 456\u2013461 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"26744_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gim.2012.44","volume":"14","author":"SN Prater","year":"2012","unstructured":"Prater, S. N. et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 14, 800\u2013810 (2012).","journal-title":"Genet Med."},{"key":"26744_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.0000000000002523","volume":"86","author":"BJ Ebbink","year":"2016","unstructured":"Ebbink, B. J. et al. Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge. Neurology 86, 1260\u20131261 (2016).","journal-title":"Neurology"},{"key":"26744_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01482-w","volume":"15","author":"JJA van den Dorpel","year":"2020","unstructured":"van den Dorpel, J. J. A. et al. Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients. Orphanet J. Rare Dis. 15, 247 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"26744_CR14","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar, L. et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology 93, e1756\u2013e1767 (2019).","journal-title":"Neurology"},{"key":"26744_CR15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg, B. L. et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest. 86, 1208\u20131220 (2006).","journal-title":"Lab. Invest."},{"key":"26744_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"LDM Pena","year":"2019","unstructured":"Pena, L. D. M. et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul. Disord. 29, 167\u2013186 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"26744_CR17","doi-asserted-by":"crossref","unstructured":"Xu, S. et al. Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight 4, e125358 (2019).","DOI":"10.1172\/jci.insight.125358"},{"key":"26744_CR18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/mt.2014.138","volume":"22","author":"G Parenti","year":"2014","unstructured":"Parenti, G. et al. A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol. Ther. 22, 2004\u20132012 (2014).","journal-title":"Mol. Ther."},{"key":"26744_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ymthe.2017.02.017","volume":"25","author":"P Kishnani","year":"2017","unstructured":"Kishnani, P. et al. Duvoglustat HCl increases systemic and tissue exposure of active acid alpha-glucosidase in Pompe patients co-administered with alglucosidase alpha. Mol. Ther. 25, 1199\u20131208 (2017).","journal-title":"Mol. Ther."},{"key":"26744_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.omtm.2017.07.004","volume":"6","author":"R Ferla","year":"2017","unstructured":"Ferla, R. et al. Non-clinical safety and efficacy of an AAV2\/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI. Mol. Ther. Methods Clin. Dev. 6, 143\u2013158 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"26744_CR21","doi-asserted-by":"crossref","unstructured":"Puzzo, F. et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci. Transl. Med. 9, eaam6375 (2017).","DOI":"10.1126\/scitranslmed.aam6375"},{"key":"26744_CR22","doi-asserted-by":"crossref","unstructured":"Cagin, U. et al. Rescue of advanced Pompe disease in mice with hepatic expression of secretable acid alpha-glucosidase. Mol. Ther. 28, 2056\u20132072 (2020).","DOI":"10.1016\/j.ymthe.2020.05.025"},{"key":"26744_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/mt.2009.195","volume":"18","author":"B Sun","year":"2010","unstructured":"Sun, B. et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol. Ther. 18, 353\u2013360 (2010).","journal-title":"Mol. Ther."},{"key":"26744_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/353180a0","volume":"353","author":"A Rahemtulla","year":"1991","unstructured":"Rahemtulla, A. et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353, 180\u2013184 (1991).","journal-title":"Nature"},{"key":"26744_CR25","doi-asserted-by":"publisher","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","volume":"273","author":"N Raben","year":"1998","unstructured":"Raben, N. et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273, 19086\u201319092 (1998).","journal-title":"J. Biol. Chem."},{"key":"26744_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood-2002-09-2889","volume":"102","author":"AM Davidoff","year":"2003","unstructured":"Davidoff, A. M., Ng, C. Y., Zhou, J., Spence, Y. & Nathwani, A. C. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102, 480\u2013488 (2003).","journal-title":"Blood"},{"key":"26744_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-8417-1-6","volume":"1","author":"M Cardone","year":"2008","unstructured":"Cardone, M. et al. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1, 6 (2008).","journal-title":"Pathogenetics"},{"key":"26744_CR28","doi-asserted-by":"publisher","first-page":"9419","DOI":"10.1073\/pnas.0902534106","volume":"106","author":"LR DeRuisseau","year":"2009","unstructured":"DeRuisseau, L. R. et al. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc. Natl Acad. Sci. USA 106, 9419\u20139424 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26744_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","volume":"80","author":"N Raben","year":"2003","unstructured":"Raben, N. et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 80, 159\u2013169 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"26744_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","volume":"14","author":"T Fukuda","year":"2006","unstructured":"Fukuda, T. et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. 14, 831\u2013839 (2006).","journal-title":"Mol. Ther."},{"key":"26744_CR31","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/cdd.2012.52","volume":"19","author":"AC Nascimbeni","year":"2012","unstructured":"Nascimbeni, A. C., Fanin, M., Masiero, E., Angelini, C. & Sandri, M. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ. 19, 1698\u20131708 (2012).","journal-title":"Cell Death Differ."},{"key":"26744_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","volume":"11","author":"JA Lim","year":"2015","unstructured":"Lim, J. A., Li, L., Kakhlon, O., Myerowitz, R. & Raben, N. Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy 11, 385\u2013402 (2015).","journal-title":"Autophagy"},{"key":"26744_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","volume":"26","author":"JA Lim","year":"2018","unstructured":"Lim, J. A., Sun, B., Puertollano, R. & Raben, N. Therapeutic benefit of autophagy modulation in Pompe disease. Mol. Ther. 26, 1783\u20131796 (2018).","journal-title":"Mol. Ther."},{"key":"26744_CR34","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1113\/JP271471","volume":"594","author":"EA Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman, E. A., Mahmoud, A. M., Khalifa, A. M. & Ali, S. S. Physiological and pathophysiological reactive oxygen species as probed by EPR spectroscopy: the underutilized research window on muscle ageing. J. Physiol. 594, 4591\u20134613 (2016).","journal-title":"J. Physiol."},{"key":"26744_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","volume":"6","author":"N Raben","year":"2002","unstructured":"Raben, N. et al. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol. Ther. 6, 601\u2013608 (2002).","journal-title":"Mol. Ther."},{"key":"26744_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/mt.2014.224","volume":"23","author":"J Lukas","year":"2015","unstructured":"Lukas, J. et al. Enzyme enhancers for the treatment of Fabry and Pompe disease. Mol. Ther. 23, 456\u2013464 (2015).","journal-title":"Mol. Ther."},{"key":"26744_CR37","doi-asserted-by":"crossref","unstructured":"Johnson, F. K. et al. First-in-human preliminary pharmacokinetic data on a novel recombinant acid \u03b1-glucosidase, ATB200, co-administered with the pharmacological chaperone AT2221, in patients with late-onset Pompe disease. In 14th Annual WORLD Symposium (2018).","DOI":"10.1016\/j.ymgme.2017.12.177"},{"key":"26744_CR38","doi-asserted-by":"crossref","unstructured":"Kishnani, P. et al. First-in-human study of advanced and targeted acid \u03b1-glucosidase (AT-GAA) (ATB200\/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial. In 15th Annual WORLD Symposium (2019).","DOI":"10.1016\/j.ymgme.2018.12.212"},{"key":"26744_CR39","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215\u20132227 (2017).","journal-title":"N. Engl. J. Med."},{"key":"26744_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani, P. S. et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99\u2013109 (2007).","journal-title":"Neurology"},{"key":"26744_CR41","doi-asserted-by":"crossref","unstructured":"Kazi, Z. B. et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight 2, e94328 (2017).","DOI":"10.1172\/jci.insight.94328"},{"key":"26744_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser, B. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J. Neurol. 264, 621\u2013630 (2017).","journal-title":"J. Neurol."},{"key":"26744_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien, K. M., Hendriksz, C. J., Roberts, M. & Sharma, R. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5 years. Mol. Genet. Metab. 117, 413\u2013418 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"26744_CR44","doi-asserted-by":"publisher","first-page":"103052","DOI":"10.1016\/j.ebiom.2020.103052","volume":"61","author":"P Colella","year":"2020","unstructured":"Colella, P. et al. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects. EBioMedicine 61, 103052 (2020).","journal-title":"EBioMedicine"},{"key":"26744_CR45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymgme.2017.12.435","volume":"123","author":"AK Desai","year":"2018","unstructured":"Desai, A. K. et al. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: clinical experience with rate escalation. Mol. Genet. Metab. 123, 92\u201396 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"26744_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s41669-019-0142-3","volume":"3","author":"B Schoser","year":"2019","unstructured":"Schoser, B. et al. A systematic review of the health economics of Pompe disease. Pharmacoecon. Open 3, 479\u2013493 (2019).","journal-title":"Pharmacoecon. Open"},{"key":"26744_CR47","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1242\/dmm.025171","volume":"9","author":"S Marco","year":"2016","unstructured":"Marco, S. et al. Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC. Dis. Model Mech. 9, 999\u20131013 (2016).","journal-title":"Dis. Model Mech."},{"key":"26744_CR48","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1093\/hmg\/ddz128","volume":"28","author":"JM Crudele","year":"2019","unstructured":"Crudele, J. M. & Chamberlain, J. S. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. 28, R102\u2013R107 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"26744_CR49","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell, J. R. et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 77, 1122\u20131131 (2020).","journal-title":"JAMA Neurol."},{"key":"26744_CR50","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh, P. B. et al. Re: \u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte. Hum. Gene Ther. 31, 787 (2020).","journal-title":"Hum. Gene Ther."},{"key":"26744_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi, F. et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419\u2013422 (2007).","journal-title":"Nat. Med."},{"key":"26744_CR52","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12875","volume":"506","author":"L Lisowski","year":"2014","unstructured":"Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382\u2013386 (2014).","journal-title":"Nature"},{"key":"26744_CR53","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1042\/BJ20050364","volume":"389","author":"Y Zhu","year":"2005","unstructured":"Zhu, Y. et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem. J. 389, 619\u2013628 (2005).","journal-title":"Biochem. J."},{"key":"26744_CR54","first-page":"723","volume":"23","author":"J Wenk","year":"1991","unstructured":"Wenk, J., Hille, A. & von Figura, K. Quantitation of Mr 46,000 and Mr 300,000 mannose 6-phosphate receptors in human cells and tissues. Biochem. Int. 23, 723\u2013731 (1991).","journal-title":"Biochem. Int."},{"key":"26744_CR55","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994\u20132004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"26744_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi, K. J. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N. Engl. J. Med. 382, 29\u201340 (2020).","journal-title":"N. Engl. J. Med."},{"key":"26744_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","volume":"17","author":"IE den Uijl","year":"2011","unstructured":"den Uijl, I. E. et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 17, 41\u201344 (2011).","journal-title":"Haemophilia"},{"key":"26744_CR58","doi-asserted-by":"publisher","first-page":"e11298","DOI":"10.15252\/emmm.201911298","volume":"12","author":"E Barbon","year":"2020","unstructured":"Barbon, E. et al. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Mol. Med. 12, e11298 (2020).","journal-title":"EMBO Mol. Med."},{"key":"26744_CR59","doi-asserted-by":"publisher","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","volume":"7","author":"R Khanna","year":"2012","unstructured":"Khanna, R. et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS ONE 7, e40776 (2012).","journal-title":"PLoS ONE"},{"key":"26744_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymthe.2017.09.001","volume":"26","author":"GD Keeler","year":"2018","unstructured":"Keeler, G. D. et al. Gene therapy-induced antigen-specific tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis. Mol. Ther. 26, 173\u2013183 (2018).","journal-title":"Mol. Ther."},{"key":"26744_CR61","doi-asserted-by":"crossref","unstructured":"Mendell, J. R. et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 78, 834\u2013841 (2021).","DOI":"10.1001\/jamaneurol.2021.1272"},{"key":"26744_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/humc.2014.2514","volume":"25","author":"PI Byrne","year":"2014","unstructured":"Byrne, P. I. et al. Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134\u2013163 (2014).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"26744_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.resp.2015.11.013","volume":"222","author":"BK Smith","year":"2016","unstructured":"Smith, B. K., Corti, M., Martin, A. D., Fuller, D. D. & Byrne, B. J. Altered activation of the diaphragm in late-onset Pompe disease. Respir. Physiol. Neurobiol. 222, 11\u201315 (2016).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"26744_CR64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/mt.2011.220","volume":"20","author":"A Ruzo","year":"2012","unstructured":"Ruzo, A. et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol. Ther. 20, 254\u2013266 (2012).","journal-title":"Mol. Ther."},{"key":"26744_CR65","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1681\/ASN.2008040406","volume":"20","author":"PA Gonzales","year":"2009","unstructured":"Gonzales, P. A. et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 20, 363\u2013379 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"26744_CR66","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0962-8924(00)01794-3","volume":"10","author":"NW Andrews","year":"2000","unstructured":"Andrews, N. W. Regulated secretion of conventional lysosomes. Trends Cell Biol. 10, 316\u2013321 (2000).","journal-title":"Trends Cell Biol."},{"key":"26744_CR67","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1089\/hum.2013.233","volume":"25","author":"G Bortolussi","year":"2014","unstructured":"Bortolussi, G. et al. Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome. Hum. Gene Ther. 25, 844\u2013855 (2014).","journal-title":"Hum. Gene Ther."},{"key":"26744_CR68","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/mt.2011.151","volume":"19","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol. Ther. 19, 2012\u20132020 (2011).","journal-title":"Mol. Ther."},{"key":"26744_CR69","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George, L. A. et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol. Ther. 28, 2073\u20132082 (2020).","journal-title":"Mol. Ther."},{"key":"26744_CR70","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne, C. et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat. Med. 26, 1096\u20131101 (2020).","journal-title":"Nat. Med."},{"key":"26744_CR71","doi-asserted-by":"crossref","unstructured":"Meliani, A. B. F. et al. Antigen-specific modulation of capsid immunogenicity with tolerogenic nanoparticles results in successful AAV vector readministration. Mol. Ther. 24, S34 (2016).","DOI":"10.1016\/S1525-0016(16)32886-6"},{"key":"26744_CR72","doi-asserted-by":"crossref","unstructured":"Corti, M. et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol. Ther. 1, 14033 (2014).","DOI":"10.1038\/mtm.2014.33"},{"key":"26744_CR73","first-page":"85","volume":"12","author":"P Colella","year":"2019","unstructured":"Colella, P. et al. AAV gene transfer with Tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate Pompe mice. Mol. Ther. 12, 85\u2013101 (2019).","journal-title":"Mol. Ther."},{"key":"26744_CR74","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi, F. et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Investig. 111, 1347\u20131356 (2003).","journal-title":"J. Clin. Investig."},{"key":"26744_CR75","first-page":"126","volume":"4","author":"SO Han","year":"2017","unstructured":"Han, S. O. et al. Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol. Ther. 4, 126\u2013136 (2017).","journal-title":"Mol. Ther."},{"key":"26744_CR76","first-page":"16083","volume":"3","author":"GQ Perrin","year":"2016","unstructured":"Perrin, G. Q. et al. Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer. Mol. Ther. 3, 16083 (2016).","journal-title":"Mol. Ther."},{"key":"26744_CR77","doi-asserted-by":"crossref","unstructured":"Bartolo, L. et al. Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity. JCI Insight 4, e127008 (2019).","DOI":"10.1172\/jci.insight.127008"},{"key":"26744_CR78","first-page":"16049","volume":"3","author":"G Ronzitti","year":"2016","unstructured":"Ronzitti, G. et al. A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Mol. Ther. 3, 16049 (2016).","journal-title":"Mol. Ther."},{"key":"26744_CR79","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/hum.2011.063","volume":"23","author":"P Zhang","year":"2012","unstructured":"Zhang, P. et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum. Gene Ther. 23, 460\u2013472 (2012).","journal-title":"Hum. Gene Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26744-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26744-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26744-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T13:43:36Z","timestamp":1726062216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26744-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26744"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26744-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M., P.C., and G.R. are inventors in patents applications concerning the treatment of Pompe disease by AAV licensed to Spark Therapeutics (WO2018046774, WO2018046775, and WO2018046775). S.M.A., J.M.L.N., and X.M.A. are inventors in a patent application describing the optimization of the secretable GAA transgene owned by Spark Therapeutics (WO2019222411). C.R.R., J.M.L.N, G.M.P., M.L., M.C., T.A., W.J.Q.III, X.M.A., S.M.A., and F.M. are either current or past employees and equity holder of Spark Therapeutics, Inc., a Roche company. H.C.V., P.S., U.C., J.F., S.B., M.N.-N., J.K.-L., L.v.W., N.D., B.G., J.C., C.A., M.S.-S., S.C., D.G., and O.B. declare no competing interests. This work was partially supported by Spark Therapeutics under a sponsored research agreement to Genethon.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6393"}}